Familial Risk of Melanoma and Links with Other Cancers

Overview

Journal Melanoma Manag

Date 2018 Sep 8

PMID 30190834

Citations 4

Authors

Kachiu C Lee

H William Higgins 2nd

Abrar A Qureshi

Affiliations

Soon will be listed here.

Abstract

The genetic risk factors for melanoma are complex and involve both familial and environmental components. Of the thousands of melanomas diagnosed each year, only a fraction are due to familial causes. These melanomas typically present in younger individuals, and may be associated with genetic factors that put these individuals at risk for other tumors. and are the most well-characterized mutations, as they have been identified in up to 40% of familial melanomas. Individuals with are also at risk for pancreatic cancer. The mutation has also been implicated in familial melanomas, breast and ovarian cancer. The , and mutations are associated with melanomas and several other familial tumors.

Citing Articles

Common skin cancers and their association with other non-cutaneous primary malignancies: a review of the literature.

Holic L Med Oncol. 2024; 41(6):157.

PMID: 38758457 DOI: 10.1007/s12032-024-02385-7.

Optically Guided High-Frequency Ultrasound Shows Superior Efficacy for Preoperative Estimation of Breslow Thickness in Comparison with Multispectral Imaging: A Single-Center Prospective Validation Study.

Varga N, Boostani M, Farkas K, Banvolgyi A, Lorincz K, Posta M Cancers (Basel). 2024; 16(1).

PMID: 38201584 PMC: 10778011. DOI: 10.3390/cancers16010157.

Study on Early Onset Melanoma and Germ-Line Mutation in CDKN2A among Patients in Imam Khomeini Hospital Complex.

Ferdosi S, Saffari M, Alishahi R, Ghanadan A, Shirkohi R Asian Pac J Cancer Prev. 2021; 22(10):3347-3353.

PMID: 34711012 PMC: 8858231. DOI: 10.31557/APJCP.2021.22.10.3347.

LncRNA MEG3 promotes melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis.

Wu L, Zhu L, Li Y, Zheng Z, Lin X, Yang C Cancer Cell Int. 2020; 20:12.

PMID: 31938020 PMC: 6954595. DOI: 10.1186/s12935-019-1087-4.

References

Mehnert J, Kluger H . Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep. 2012; 14(5):449-57. PMC: 4447200. DOI: 10.1007/s11912-012-0249-5. View

Hill V, Gartner J, Samuels Y, Goldstein A . The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet. 2013; 14:257-79. DOI: 10.1146/annurev-genom-091212-153429. View

Veronese L, Tournilhac O, Callanan M, Prie N, Kwiatkowski F, Combes P . Telomeres and chromosomal instability in chronic lymphocytic leukemia. Leukemia. 2012; 27(2):490-3. DOI: 10.1038/leu.2012.194. View

Petersen G, Vachon C . Genetic epidemiology of melanoma: of consortia and conundrums. J Natl Cancer Inst. 2002; 94(12):872-3. DOI: 10.1093/jnci/94.12.872. View

Ragnarsson-Olding B . Primary malignant melanoma of the vulva--an aggressive tumor for modeling the genesis of non-UV light-associated melanomas. Acta Oncol. 2004; 43(5):421-35. DOI: 10.1080/02841860410031372. View

Moloney F, Guitera P, Coates E, Haass N, Ho K, Khoury R . Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study. JAMA Dermatol. 2014; 150(8):819-27. DOI: 10.1001/jamadermatol.2014.514. View

Helgadottir H, Hoiom V, Jonsson G, Tuominen R, Ingvar C, Borg A . High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet. 2014; 51(8):545-52. PMC: 4112445. DOI: 10.1136/jmedgenet-2014-102320. View

Harbour J, Onken M, Roberson E, Duan S, Cao L, Worley L . Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010; 330(6009):1410-3. PMC: 3087380. DOI: 10.1126/science.1194472. View

Abdel-Rahman M, Pilarski R, Cebulla C, Massengill J, Christopher B, Boru G . Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011; 48(12):856-9. PMC: 3825099. DOI: 10.1136/jmedgenet-2011-100156. View

10.

. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91(15):1310-6. DOI: 10.1093/jnci/91.15.1310. View

11.

Puig-Butille J, Escamez M, Garcia-Garcia F, Tell-Marti G, Fabra A, Martinez-Santamaria L . Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget. 2014; 5(6):1439-51. PMC: 4039222. DOI: 10.18632/oncotarget.1444. View

12.

Zuo L, Weger J, Yang Q, Goldstein A, Tucker M, Walker G . Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996; 12(1):97-9. DOI: 10.1038/ng0196-97. View

13.

Scott R, Vajdic C, Armstrong B, Ainsworth C, Meldrum C, Aitken J . BRCA2 mutations in a population-based series of patients with ocular melanoma. Int J Cancer. 2002; 102(2):188-91. DOI: 10.1002/ijc.10693. View

14.

Murali R, Wiesner T, Scolyer R . Tumours associated with BAP1 mutations. Pathology. 2013; 45(2):116-26. DOI: 10.1097/PAT.0b013e32835d0efb. View

15.

Sheppard K, McArthur G . The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013; 19(19):5320-8. DOI: 10.1158/1078-0432.CCR-13-0259. View

16.

Ismail I, Davidson R, Gagne J, Xu Z, Poirier G, Hendzel M . Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 2014; 74(16):4282-94. DOI: 10.1158/0008-5472.CAN-13-3109. View

17.

Lynch H, Brand R, Hogg D, Deters C, Fusaro R, Lynch J . Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer. 2002; 94(1):84-96. DOI: 10.1002/cncr.10159. View

18.

Chang S . Cancer chromosomes going to POT1. Nat Genet. 2013; 45(5):473-5. PMC: 4040961. DOI: 10.1038/ng.2617. View

19.

Wiesner T, Obenauf A, Murali R, Fried I, Griewank K, Ulz P . Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011; 43(10):1018-21. PMC: 3328403. DOI: 10.1038/ng.910. View

20.

Forsea A, Del Marmol V, de Vries E, Bailey E, Geller A . Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol. 2012; 167(5):1124-30. DOI: 10.1111/j.1365-2133.2012.11125.x. View